MwanzoGNLX • NASDAQ
add
Genelux Corp
$ 3.92
Baada ya Saa za Kazi:(2.04%)+0.080
$ 4.00
Imefungwa: 27 Jan, 16:16:56 GMT -5 · USD · NASDAQ · Kanusho
Bei iliyotangulia
$ 3.96
Bei za siku
$ 3.68 - $ 4.74
Bei za mwaka
$ 1.60 - $ 12.12
Thamani ya kampuni katika soko
135.39M USD
Wastani wa hisa zilizouzwa
elfu 174.68
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
NASDAQ
Habari za soko
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | — | — |
Matumizi ya uendeshaji wa biashara | 6.94M | 30.79% |
Mapato halisi | -6.47M | -20.99% |
Kiwango cha faida halisi | — | — |
Mapato kwa kila hisa | -0.19 | 5.00% |
EBITDA | -6.88M | -33.07% |
Asilimia ya kodi ya mapato | — | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 34.06M | 14.02% |
Jumla ya mali | 40.27M | 18.19% |
Jumla ya dhima | 7.18M | -28.52% |
Jumla ya hisa | 33.09M | — |
hisa zilizosalia | 34.10M | — |
Uwiano wa bei na thamani | 4.08 | — |
Faida inayotokana na mali | -40.61% | — |
Faida inayotokana mtaji | -46.27% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -6.47M | -20.99% |
Pesa kutokana na shughuli | -5.75M | -71.22% |
Pesa kutokana na uwekezaji | 3.99M | 1,541.16% |
Pesa kutokana na ufadhili | 0.00 | -100.00% |
Mabadiliko halisi ya pesa taslimu | -1.76M | -164.35% |
Mtiririko huru wa pesa | -3.23M | -117.71% |
Kuhusu
Genelux Corporation is a publicly traded late clinical-stage company developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity.
The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec.
The company is currently entered its pivot Phase 3 study in Platinum resistant/refractory ovarian cancer. Trial design based on VIRO-15 Phase 2 trial which showed independent anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the TME. Wikipedia
Ilianzishwa
2001
Makao Makuu
Tovuti
Wafanyakazi
25
